ESR1 and breast neoplasm: Clinically relevant oral doses of fingolimod (1 mg/kg) suppressed development, progression, and aggressiveness of spontaneous breast tumors in MMTV-PyMT transgenic mice and reduced HDAC activity that reactivated estrogen receptor-α (ERα) expression (Hait et al., 2015).